Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 4784.30% ano a ano.
Subavaliada
O PE mais recente da empresa é -2.18, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 114.13M ações, um aumento de 37.39% em relação ao trimestre anterior.
Mantido por Steven Cohen
O Super Investidor Steven Cohen possui 5.85M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 1.12.